Charles River Laboratories International, Inc. (CRL) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, Charles River Laboratories International reported revenue of $4.02B, down 0.9% from $4.05B the year before. Net income was -$144.3M (a -3.6% net margin), or -$2.91 per diluted share. Gross margin was 90.6% and operating margin was 0.6%. Operating activities generated $737.6M of cash, leaving $518.5M of free cash flow. At fiscal year end, Charles River Laboratories International held $7.14B in total assets against $3.92B in total liabilities, including $213.8M of cash and equivalents.
Open the full interactive Charles River Laboratories International financials → Quarterly statements, key ratios, valuation history and price charts.
Charles River Laboratories International Key Stats
| Share Price | $299.02 |
|---|---|
| Market Cap | $14.36B |
| Revenue YoY Growth | -0.9% |
| 52-Week Range | $149.93 – $310.77 |
| Shares Outstanding | 48.0 million (basic, 2026 Q2) |
Charles River Laboratories International Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Cost of Goods Sold | $317.2M | $368.0M | $370.1M | $330.9M | $372.4M | $377.3M |
| Gross Profit | $2.61B | $3.17B | $3.61B | $3.80B | $3.68B | $3.64B |
| Operating Income | $432.7M | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M |
| Pre-Tax Income | $447.1M | $480.7M | $623.0M | $581.3M | $93.1M | -$99.5M |
| Income Tax | $81.8M | $81.9M | $130.4M | $100.9M | $67.8M | $42.7M |
| Net Income | $364.3M | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
| Diluted EPS | $7.20 | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 |
Charles River Laboratories International Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.00B | $994.2M | $995.8M | $1.00B |
| Net Income | $54.4M | -$276.6M | -$14.8M | -$1.5M |
| Diluted EPS | $1.10 | -$5.58 | -$0.30 | -$0.03 |
Charles River Laboratories International Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $228.4M | $241.2M | $233.9M | $276.8M | $194.6M | $213.8M |
| Current Assets | $1.20B | $1.27B | $1.44B | $1.61B | $1.40B | $1.45B |
| Total Assets | $5.49B | $7.02B | $7.60B | $8.20B | $7.53B | $7.14B |
| Current Liabilities | $839.8M | $1.03B | $1.09B | $1.06B | $994.1M | $1.12B |
| Total Long-Term Debt | $1.98B | $2.67B | $2.71B | $2.65B | $2.24B | $2.14B |
| Total Liabilities | $3.35B | $4.43B | $4.58B | $4.54B | $4.02B | $3.92B |
| Shareholders' Equity | $2.11B | $2.53B | $2.98B | $3.60B | $3.46B | $3.16B |
Charles River Laboratories International Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $546.6M | $760.8M | $619.6M | $683.9M | $734.6M | $737.6M |
| Cash From Investing | -$601.5M | -$1.44B | -$607.9M | -$563.2M | -$245.1M | -$209.3M |
| Cash From Financing | $47.2M | $672.6M | -$42.4M | -$85.5M | -$550.9M | -$536.7M |
| Free Cash Flow | $380.0M | $532.0M | $294.9M | $365.4M | $501.6M | $518.5M |
Figures from Charles River Laboratories International's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Charles River Laboratories International financials page for every line item.
Charles River Laboratories International Company Profile
| Ticker | CRL |
|---|---|
| Exchange | NYSE |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | Wilmington, Massachusetts |
| Fiscal Year End | December 27 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001100682 |
Frequently Asked Questions
What was Charles River Laboratories International's revenue in fiscal 2025?
Charles River Laboratories International (CRL) reported revenue of $4.02B for fiscal 2025.
What is Charles River Laboratories International's annual revenue history?
Charles River Laboratories International's annual revenue by fiscal year: 2020: $2.92B; 2021: $3.54B; 2022: $3.98B; 2023: $4.13B; 2024: $4.05B; 2025: $4.02B.
What was Charles River Laboratories International's net income in fiscal 2025?
Charles River Laboratories International reported net income of -$144.3M for fiscal 2025.
What was Charles River Laboratories International's earnings per share (EPS) in fiscal 2025?
Charles River Laboratories International's diluted EPS was -$2.91 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Charles River Laboratories International generate in fiscal 2025?
Charles River Laboratories International generated $518.5M of free cash flow in fiscal 2025.
What was Charles River Laboratories International's revenue last quarter?
In its most recent reported quarter (2026 Q2), Charles River Laboratories International reported revenue of $1.00B.
How much debt does Charles River Laboratories International have?
Charles River Laboratories International reported $2.14B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Charles River Laboratories International are outstanding?
Charles River Laboratories International reported a weighted average of 48.0 million basic shares outstanding in 2026 Q2.
What is Charles River Laboratories International's market cap?
Based on its latest closing price, Charles River Laboratories International (CRL) has a market capitalization of about $14.36B.
When does Charles River Laboratories International's fiscal year end?
Charles River Laboratories International's fiscal year end, as registered with the SEC, is December 27.
Where is Charles River Laboratories International headquartered?
Charles River Laboratories International lists its business address in Wilmington, Massachusetts in its SEC filings.
Charles River Laboratories International Competitors & Similar Companies
See all 12 Commercial Physical & Biological Research (Services) companies →